Top Markets
#1 EXOD EXOD +56.80%
#2 Arowana Arowana +8.48%
#3 Harmony Harmony +7.27%
#4 Fake World Assets Fake World Assets +6.48%
#5 Cysic Cysic +5.83%
#6 Orochi Network Orochi Network +3.92%
#7 Dual Dual +3.59%
#8 Fabric Protocol Fabric Protocol +3.54%
#9 Figure Heloc Figure Heloc +3.49%
#10 TAGGER TAGGER +3.35%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Evgen Pharma plc Evgen Pharma plc

Evgen Pharma plc

EVG
Rank in Stocks #38016
Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates... Evgen Pharma plc, a UK-based pharmaceutical company founded in 2014, operates at the clinical development stage, concentrating on the creation of sulforaphane-based medications. Its mission is to combat various cancers and inflammatory conditions. The firm utilizes its proprietary Sulforadex technology, which is engineered to stabilize sulforaphane, in its product development. SFX-01 stands as their principal drug candidate, currently in Phase II clinical trials for metastatic breast cancer and Phase Ib/IIa trials for glioblastoma. Furthermore, SFX-01 is being investigated in preclinical stages for haematological malignancies and analogous disorders. The company also offers out-licensing services for its innovative technology.
Share Price
$0.00953895
Last synced: 2024-05-22
Market Cap
$1.28M
Change (1 day)
0.06%
Change (1 year)
0.00%
Country
GB
Trade Evgen Pharma plc (EVG)

Category

Healthcare
P/E ratio for Evgen Pharma plc (EVG)
P/E ratio as of 2026 TTM: 0
According to Evgen Pharma plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Evgen Pharma plc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.